Fig. 2.

(DA) daidzein reverses (LV) lovastatin-induced C2C12 myotubes atrophy. A C2C12 myotubes were administered with 10 µmol/L lovastatin and different concentration of daidzein for 24 h and incubated CCK-8 for 1.5 h, and tested with Microplate reader(n = 6). B C2C12 myotubes were administered with 10 µmol/L lovastatin for 24 h, MyHC was stained, and inverted microscope were used to capture the images. C2C12 myotubes were calculated and analyzed with ImageJ. C–E C2C12 myotubes were treated with lovastatin + 50 µmol/L daidzein for 24 h and cellular protein and RNA were collected. Immunoblotting and RT-qPCR were used to test the expression level of Atrogin-1 and MuRF-1. The mean ± SEM was used to represent the data. *p < 0.05; **p < 0.01; ***p < 0.001, (n = 3)